1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
BioNxt Solutions Inc.

BioNxt Solutions Inc.

BNXT.CN
BioNxt Solutions Inc.CA flagCanadian Securities Exchange
0.32
CAD
- -
- -
41.60MMarket Cap
BioNxt Solutions Inc.
BNXT.CN
(Canadian Securities Exchange)

Recent

price

0.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.17
-0.3
-0.29
-0.15
-0.08
-0.05
-0.06
-0.08
Basic EPS, GAAP
-0.01
-0.08
-0.18
-0.18
-0.07
-0.05
-0.03
-0.04
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.12
0.08
-0.01
-0.06
-0.12
-0.09
-0.11
-0.12
-0.12
Book Value per Share
0.15
0.1
0.07
-0.06
-0.05
-0.05
-0.07
-0.08
-0.06
Tangible Book Value per Share
47
45
57
70
84
99
111
118
120
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-3,419.32
-4,282.81
-5,692.9
-2,032.3
-1,715.86
-16,925.66
- -
- -
Operating Margin (%)
- -
1
1
1
- -
- -
- -
- -
- -
Depreciation Expense
-1
-8
-17
-21
-12
-8
-5
-7
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-3,684.77
-4,886.32
-7,203.23
-4,160.84
-2,074.68
-19,683.18
- -
- -
Profit Margin (%)
2
-1
2
-3
-1
-6
-7
-6
-7
Working Capital
1
1
3
2
4
- -
2
4
1
LT Debt
8
6
4
2
-4
-5
-8
-9
-7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-162.46
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3
2
5
LT Borrowings
6
4
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
121
122
130
Market Capitalization
104
74
59

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
6
7
Payables & Accruals
1
4
1
ST Debt
3
2
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-61.97%
19.13%
Free Cash Flow
- -
-3%
71.25%
Net Income, GAAP
- -
-10.88%
32.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.05
2025
-0.02
-0.01
-0.01
- -
-0.06
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Vinergy Capital Inc. (VNNYF)
Verano Holdings Corp. (VRNO.CN)
Gufic Biosciences Limited (GUFICBIO.NS)
Luff Enterprises Ltd. (LUFF.CN)
Thunder Energies Corporation (TNRG)
Sumitomo Pharma Co., Ltd. (DNPUF)
Business
BioNxt Solutions Inc. BioNxt Solutions Inc. (CSE:BNXT) operates as a clinical-stage bioscience company that researches, develops, manufactures and sells next-generation drug formulations and delivery systems, including sublingual thin films, transdermal patches and oral dissolvable technologies for neurological, autoimmune and neurodegenerative diseases; its pipeline features BNT23001 for multiple sclerosis, BNT23002 for myasthenia gravis, BNT24002 for lupus nephritis, BNT24003 for rheumatoid arthritis, BNT24004 for longevity and anti-aging, and semaglutide oral formulations, alongside diagnostic screening tests for infectious diseases and oral health, psychedelic medicine production including psilocybin and mescaline for mental health conditions, and standardization of active pharmaceutical ingredients for neurological applications. The company maintains research and development operations in North America and Europe with a primary focus in Germany, Austria and Switzerland, serving licensed growers, processors, dispensaries and government agencies while targeting commercialization through licensing deals or acquisitions by major pharmaceutical firms. Founded as XPhyto Therapeutics and renamed BioNxt Solutions Inc. in 2022 with headquarters in Vancouver, Canada, BioNxt recently receives European Patent Office intention-to-grant notice for its oral cladribine sublingual thin-film in November 2025, advances bioequivalence studies for human trials, acquires state-of-the-art coating and cutting equipment in 2024 to expand European manufacturing capacity, considers artificial intelligence acquisition to accelerate development, finalizes debt settlements and completes a roughly $4 million private placement, and pursues partnerships in obesity treatments and rotigotine patches for Parkinson's disease.

Company News

APIChatGPT

  • accessnewswire.com

    BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

  • accessnewswire.com

    BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments